Last reviewed · How we verify
ketoprofen and cyclobenzaprine association
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and inflammation, while cyclobenzaprine is a muscle relaxant that acts as a central nervous system depressant, affecting the brain's motor control centers.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and inflammation, while cyclobenzaprine is a muscle relaxant that acts as a central nervous system depressant, affecting the brain's motor control centers. Used for Relief of pain and inflammation, Muscle spasms.
At a glance
| Generic name | ketoprofen and cyclobenzaprine association |
|---|---|
| Also known as | EMS association |
| Sponsor | EMS |
| Drug class | NSAID and muscle relaxant |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Ketoprofen's mechanism of action involves the inhibition of cyclooxygenase enzymes, specifically COX-1 and COX-2, which are responsible for the production of prostaglandins. Prostaglandins are mediators of inflammation and pain. Cyclobenzaprine, on the other hand, works by affecting the brain's motor control centers, leading to relaxation of skeletal muscles. This results in reduced muscle spasms and pain.
Approved indications
- Relief of pain and inflammation
- Muscle spasms
Common side effects
- Gastrointestinal upset
- Drowsiness
- Dizziness
Key clinical trials
- Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment (PHASE3)
- Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ketoprofen and cyclobenzaprine association CI brief — competitive landscape report
- ketoprofen and cyclobenzaprine association updates RSS · CI watch RSS
- EMS portfolio CI